Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Financing Receivable, Past Due [Line Items]
Revenue	$ 13,613	$ 9,560		$ 31,206	$ 40,703
Other revenue	1			481	496
Interest expense	82	53		242	292
Manufacturing, research and development	1,792	2,487		5,173	5,577
Depreciation and amortization expense	634	812		1,964	3,305
General and administrative	4,349	3,580		10,527	9,825
Other income, net	1,801	128		89	2,235
Income tax expense	1,942	513		3,211	4,980
Net income (loss)	6,616	2,243	$ 2,243	10,659	19,602
Change in fair value of acquisition-related contingent consideration					(147)
Financing Receivable [Member]
Financing Receivable, Past Due [Line Items]
Revenue	8,502	9,373		25,745	29,857
Other revenue
Interest expense	82	53		242	292
Manufacturing, research and development
Depreciation and amortization expense
General and administrative	115	90		219	2,034
Other income, net	1,801	128		89	2,235
Income tax expense
Net income (loss)	10,106	9,358		25,373	29,766
Change in fair value of acquisition-related contingent consideration
Pharmaceutical Development Services [Member]
Financing Receivable, Past Due [Line Items]
Revenue	5,111	187		5,461	10,846
Other revenue				480	496
Interest expense
Manufacturing, research and development	1,792	2,487		5,173	5,577
Depreciation and amortization expense	632	810		1,961	3,300
General and administrative	843	999		2,783	3,088
Other income, net
Income tax expense
Net income (loss)	1,844	(4,109)		(3,976)	(476)
Change in fair value of acquisition-related contingent consideration					(147)
Holding Company And Other [Member]
Financing Receivable, Past Due [Line Items]
Revenue
Other revenue	1			1
Interest expense
Manufacturing, research and development
Depreciation and amortization expense	2	2		3	5
General and administrative	3,391	2,491		7,525	4,703
Other income, net
Income tax expense	1,942	513		3,211	4,980
Net income (loss)	$ (5,334)	$ (3,006)		$ (10,738)	(9,688)
Change in fair value of acquisition-related contingent consideration